Microsaic Systems Share Discussion Threads

[moneymunch] 27/4/2018 06:36

Cheers, all bodes well and highly encouraging that miniaturisation is highlighted as a prominent factor in fuelling the growth in MS....and so Microsaic couldn't be better placed imho and sooner or later this current rockbottom bargain low share price will be a distant memory....more good news very likely, transformational news in the pipeline. Gl :-)

[k1ngkonggb] 26/4/2018 20:20

Excellent post MM......


The global clinical mass spectrometry market is estimated to be valued at US$ 4,982.5 million in 2017 and is expected to witness a CAGR of 7.3% over the forecast period (2017 – 2025).

[splatted] 26/4/2018 20:19

Nice one mm

[moneymunch] 26/4/2018 18:25

PHARMACEUTICAL

Clinical Mass Spectrometry Market to receive overwhelming hike in Revenues by 2019

April 26, 2018

...........

Technological advancements leading to new product launch is a prominent factor fueling growth of the clinical mass spectrometry market

Advancements in technology includes miniaturization of mass spectrometry instruments  and increasing automation of the entire spectrometric unit to reduce human efforts and improve efficiency of the instruments. The fully automated analyzer launched by Thermo Fisher in June 2017, is a step closer to achieve entirely automated systems in the mass spectrometry market that can be customized easily to be compatible with the laboratory information systems.

[moneymunch] 26/4/2018 08:03

Microsaic's CEO

"As I've mentioned to you before, we are very pleased to say that progress is being made with one of the foremost companies in scientific instrumentation in bioprocessing. and in December, we completed a technical feasibility stage, we took the project forward into the technical integration phase."

In the short term, our technology is going to be integrated with a wide range of techniques, it's probably worth mentioning some of those, particularly in terms of chromatography.

That is preparative flash chromatography, liquid chromatography and also think layer chromatography but also in capillary electrophoresis and we're particularly interested in online reaction monitoring.

All those techniques are becoming increasingly popular to hyphenate with mass spec especially as target compounds are becoming more complex and by that, I mean targets such as peptides, small proteins, lipids and indeed a range of many other metabolites.

This is going to be done through partnerships across many geographies; Europe, North America and Asia, and that's both through OEM's and also through value-added distributors who don't currently have mass spectrometry as part of their offering and want to partner with someone to offer seamless integration with mass spec.

[moneymunch] 26/4/2018 07:48

"a flexible chip format and can be integrated with existing products for a seamless workflow".......sounds familiar???.... An instant multi-bag if Thermo Fisher was confirmed as Microsaic's global bio pharma partner. Gla ;-)


Thermo Fisher Scientific Reports 23 Percent Revenue Growth in Q1
Apr 25, 2018
| staff reporter

This article has been updated with additional information from Thermo Fisher Scientific's earnings call.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today reported 23 percent growth in revenues for the first quarter, driven by strong results across all of its business segments.

"We achieved excellent growth in revenue and earnings," said President and CEO Marc Casper during a conference call this morning to discuss the company's financial results. "Our team executed well to capitalize on the good market conditions, and we continued to successfully execute our growth strategy. ... Our great performance in Q1 sets us up to deliver another outstanding year."

Thermo Fisher reported $5.85 billion in total revenues for the first quarter, up 23 percent from $4.77 billion during the same period last year. Revenues beat expectations by Wall Street analysts of $5.63 billion. Organic revenue grew 7 percent, acquisitions contributed 12 percent to revenue growth, and currency effects increased revenue by 4 percent.

.........

Finally, laboratory products and services revenue, which include the Patheon business that Thermo Fisher acquired last August, grew 42 percent to $2.41 billion compared to $1.70 billion in Q1 of 2017. This segment, which grew 6 percent organically, saw strong growth in its clinical trial logistics and research channel businesses.

During the call, Casper pointed out that recent products contributed to the revenue growth, among them the Thermo Scientific Orbitrap Q Exactive HF mass spectrometer. He also noted several new product launches, for example, the Ion GeneStudio S5 series of next-generation sequencers, which he said feature a flexible chip format and can be integrated with existing products for a seamless workflow. He also mentioned the company's expanding Oncomine portfolio of liquid biopsy and immuno-oncology assays that help researcher bring new cancer diagnostics to the clinic.

[moneymunch] 26/4/2018 06:28

Microsaic
@Microsaic
·
Feb 1
Our Mass Detector integrates seamlessly with your chromatography, as seen here with #Gilson HPLC. With our technology, no large, noisy external roughing pumps are needed, no cumbersome exhaust is needed, and with low nitrogen and solvent consumption! Truly compact #massspec



Today, Gilson remains family owned, and manufactures purification systems, automated liquid handlers, pipettes (including the world-renowned PIPETMAN® brand of pipettes), fraction collectors, solid phase extraction (SPE) systems, detectors, injectors, and much more. From academia to industry, Gilson
delivers high-quality, dependable solutions to researchers around the world.

Since 1957, Gilson’s world headquarters has been located in Middleton, WI. Gilson has expanded and opened new Centers of Excellence to keep up with global demand. In 1963, Gilson opened a manufacturing facility, Gilson S.A.S. northeast of Paris in Villiers-le-Bel, France. In 2013, Pure Lab Plastics, a laboratory plastics manufacturer, joined the Gilson organization and in early 2017, another manufacturing facility opened in Vannes, France, Gilson Purification, S.A.S. Gilson also has local sales and service teams that include a vast distribution network in countries throughout North and South America, Europe, Middle East, Africa, (EMEA) and Asia Pacific (APAC).



Microsaic's product labelled as Gilson.

[moneymunch] 25/4/2018 11:58

More commercial deals in the pipeline more than likely, and progress and fine detail on the recent deals would be most welcome....and news on the BIG one at anytime....the first phase of the collaboration with their global biopharma partner, the feasibility study, lasted 7 to 8 months from April 2017 until confirmation by Rns 13/12/17 that the collaboration agreement had been extended for product integration with their partner's equipment and for further validation by their partner's BIG pharma end users, and so we're already 5 plus months into this phase from the last update....Tick Tock Boom.....Gla holders;-)

[moneymunch] 25/4/2018 11:39

Our TERN coming soon....Tick Tock Boom. Gla holders...On and Up!!! ;-)

[moneymunch] 23/4/2018 20:06

New minaturised/micro product launches by Shimadzu UK....Colin Jump, Microsaic's previous CEO was MD at Shimadzu for 11 years before joining Microsaic and so maybe a connection to Microsaic's technology!!!??? Gla ;-)

[moneymunch] 23/4/2018 15:32

Potentially/ presumably of benefit to Microsaic and its partners!!!??? GLA:-)


MedTech

FDA floats relaxation of regulations to encourage use of mass spectrometry to identify microorganisms

Apr 23, 2018 7:58am

    

The FDA is planning to loosen the regulatory requirements on mass spectrometry devices to increase their use in the identification of microorganisms. Agency officials outlined the plan after signing off on the use of a mass spectrometry device in the identification of the emerging drug-resistant yeast, Candida auris (C. auris).

Under the FDA’s proposals, the first successful filing covering a microorganism identification system process would clear the path for future applicants. The FDA would exempt certain processes covered by these subsequent filings from additional premarket review, enabling companies to more easily gain clearance to sell devices with expanded microorganism identification capabilities.

Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health, thinks the revised regulatory approach can further fuel interest in the use of mass spectrometry at clinical microorganism-identification laboratories.

“Although mass spectrometry technology has been a powerful scientific tool since the 1980s, it is only within that the last five years that it has been effectively used for the identification of microbiological organisms,” St. Pierre said in a statement. “The FDA has confidence in this technology and recognizes the need to rapidly address outbreaks both for C. auris and for other pathogenic microorganisms.̶1;

The FDA proposed the regulatory rethink alongside news of the authorization of the use of a C. auris test under the premarket review pathway. Bruker Daltonik got the FDA nod to add C. auris to the hundreds of species covered by its Bruker Maldi Biotyper CA system after the device identified the yeast 100% of the time in a 28-sample study.

Bruker’s device identifies microorganisms by ionizing them with a laser to generate a spectrum. This spectrum is compared to a reference organism database to enable its identification. ;

The FDA sees the availability of a device that can quickly identify C. auris and other microorganisms aiding efforts to manage outbreaks. In the case of C. auris, these outbreaks can have severe consequences. The former acting head of the CDC called the yeast a “catastrophic threat” last year. Hospital wards in the United Kingdom and elsewhere have struggled to control outbreaks of the yeast, leading to multiyear problems.

[moneymunch] 23/4/2018 08:47

Big bounce coming in anticipation. Gla holders....On and Up!!! :-)

[beetroot juice] 23/4/2018 08:39

MSYS is Starting to become noticed and to be on Shrewed investors radars. More News coming here very soon. share price is beginning to look like its about to RE-Rate.

Looking GREAT...Big one on its way...

[splatted] 21/4/2018 14:33

Yep china,germany then america. Not over there till june though arent they?

[k1ngkonggb] 20/4/2018 19:49

Another distribution deal...perhaps in the States now!!!

[splatted] 20/4/2018 18:02

I guess not :-)...... :-)))

[moneymunch] 20/4/2018 16:57

Roll on Monday, more of the same next week with any luck....more good news very likely.......and one more week closer to the BIG one... Gla ;-)

[moneymunch] 20/4/2018 14:11

and here we go again at Microsaic....profit takers mopped up.....more upside on its way. Gl :-)

[cudmore] 20/4/2018 14:08

Splatted

It’s hardly pump and dump.....look at the Mkt Cap and you’ll see why PFX is the one to be in. Here we go again.....get in quick!

[cudmore] 20/4/2018 12:28

DFX about to take its next leap....get in quick!!

[moneymunch] 20/4/2018 11:48

Very likely KK on disclosure of Microsaic's global biopharma partner on successful technology trials, and a massive re-rate in the meantime from this rockbottom bargain low share price in anticipation and to reflect true value and potential at the very least. Gl :-)

[cudmore] 20/4/2018 11:36

Look at DFX go!

[k1ngkonggb] 20/4/2018 11:36

Money,

With all these new distribution deals coming on board and with the imminent Bio Pharma announcement, the potential is massive. Could we see share price of historic levels??

[splatted] 20/4/2018 11:36

Anything to say idiot???